|Day Low/High||65.77 / 68.62|
|52 Wk Low/High||13.53 / 95.21|
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
An effective Covid-19 will be a game-changer, but charts say the bottom-line impact may not be as significant as previously believed.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Plus, Veeva Systems reports stellar results and ups its guidance.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
The whole group has run and the guidance from Clorox does show, more than anything, that nobody knows.
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
In a 'normal' recession, these would be real losers -- but right now? They look like numero 'UNO'.
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Plus, why shares of vaccine maker Moderna are taking a hit.
Here is a summary of this week's major macroeconomic events: The Positives 1) Moderna , while still having to progress thru phase 3 trials, reported positive antibody results from phase 1 data and brings us a step closer to that hoped for vaccine....
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
FAANG stocks lag while the Russell rises, bringing divergences and questions.
A Fed governor speaks of accommodation, and AMC Entertainment's bond maneuvers serve as a warning to those who swim in the high-yield pool.
* Much like the Wild West, the market's action has turned unpredictable and volatile -- with little of a thematic character, save trading within a defined range and with some outstanding (and speculative) characters. The encouraging announcement of ...
Stock picking continues to be the most productive approach as market timers are battered and bruised once again.
This is pretty much exactly what you get when you have so much positive research.